The Galapagos Group
The Galapagos Group
An overview of Galapagos, its strategy and portfolio in 2014
In 2014, Galapagos made the transition from a hybrid service and pipeline company into a clinical stage R&D biotech that develops drugs with novel modes of action for high unmet medical needs.Onno van de Stolpe
CEO of Galapagos
An overview of Galapagos, its strategy and portfolio in 2014